Posts Tagged: "Opvido"

Bristol-Myers Squibb, Exelixis drugs to aid in fight against kidney cancer

Bristol-Myers Squibb was able to move on in clinical trials of its cancer drug Opvido more quickly than anticipated after kidney cancer patients who were administered the medication showed superior overall survival compared to those patients who were not on an Opvido regimen. Opvido, which has already been approved by the U.S. Food and Drug Administration for the treatment of advanced melanomas and lung cancers, is an inhibitor of the protein known as programmed cell death protein 1, or PD-1. PD-1 inhibits the response of T cell lymphocytes, making it more difficult for an immune system to target a tumor.